Xgeva and Psoriasis - a phase IV clinical study of FDA data

Summary:

Psoriasis is reported as a side effect among people who take Xgeva (denosumab), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Palbociclib, and have Breast cancer metastatic.

The phase IV clinical study analyzes which people have Psoriasis when taking Xgeva. It is created by eHealthMe based on reports of 37,636 people who have side effects when taking Xgeva from the FDA, and is updated regularly.

What is Xgeva?

Xgeva has active ingredients of denosumab. It is often used in breast cancer. eHealthMe is studying from 37,717 Xgeva users. Check the latest studies of Xgeva.

What is Psoriasis?

Psoriasis (immune-mediated disease that affects the skin) is found to be associated with 1,473 drugs and 1,695 conditions by eHealthMe. Check the latest studies of Psoriasis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 03, 2026

37,636 people reported to have side effects when taking Xgeva.
Among them, 35 people (0.09%) have Psoriasis.

Among these 35 people:

How long have people been on Xgeva when they have Psoriasis? *

What is the gender of people who have Psoriasis when taking Xgeva? *

female: 64.71 %
male: 35.29 %

What is the age of people who have Psoriasis when taking Xgeva? *

What are other drugs people take besides Xgeva? *

What are other side effects people have besides Psoriasis? *

Joint Pain: 15 people, 42.86%
Nausea (feeling of having an urge to vomit): 15 people, 42.86%
Back Pain: 13 people, 37.14%
Chills (felling of cold): 12 people, 34.29%
Musculoskeletal Discomfort (discomfort in the body's muscles, joints, tendons, ligaments and nerves): 12 people, 34.29%
Oral Mucosal Erythema (redness of the mucous membrane of mouth): 12 people, 34.29%
Fever: 12 people, 34.29%
Rash Erythematous (redness of the skin): 12 people, 34.29%
Fall: 12 people, 34.29%
Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters): 12 people, 34.29%

What are the existing conditions these people have? *

Breast Cancer Metastatic: 18 people, 51.43%
Prostate Cancer: 6 people, 17.14%
Vaginal Infection: 2 people, 5.71%
Mucosal Inflammation (infection of mucous membrane): 2 people, 5.71%
Bone Pain: 2 people, 5.71%
Headache (pain in head): 2 people, 5.71%
Indigestion: 2 people, 5.71%
Lung Cancer - Non-Small Cell (lung cancer): 2 people, 5.71%
Multiple Myeloma (cancer of the plasma cells): 1 person, 2.86%
Nausea (feeling of having an urge to vomit): 1 person, 2.86%

* Approximation only. Some reports may have incomplete information.

Do you take Xgeva and have Psoriasis?

- Check whether Psoriasis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Xgeva:

Xgeva (37,717 reports)

Psoriasis treatments and more:

Psoriasis (508,164 reports)

Browse all side effects of Xgeva:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Psoriasis:

Psoriasis (1,473 drugs)

Browse all the conditions that are associated with Psoriasis:

Psoriasis (1,695 conditions)

Related publications that referenced our studies

Mohagheghi MA, Omranipur R, Ensani F, Ghannadan A, Shahriaran S, Samiee F, Sedighi Z, "A Case of Advanced Unicentric Retroperitoneal Castleman's Disease, Associated With Psoriasis", Acta Medica Iranica, 2017 May .
Chiriac A, Brzezinski P, Stolnicu S, Podoleanu C, Moldovan C, Molnar C, Taranu T, "Eosinophilia–A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis", Journal of Dermatological Treatment, 2016 Mar .
Malisiewicz B, Murer C, Schmid JP, French LE, Schmid-Grendelmeier P, Navarini AA, "Eosinophilia during psoriasis treatment with TNF antagonists", Dermatology, 2013 Jan .
Mohagheghi MA, Omranipur R, Ensani F, Ghannadan A, Shahriaran S, Samiee F, Sedighi Z, "A Case of Advanced Unicentric Retroperitoneal Castleman's Disease, Associated With Psoriasis", Acta Medica Iranica, 2017 May .
Chiriac A, Brzezinski P, Stolnicu S, Podoleanu C, Moldovan C, Molnar C, Taranu T, "Eosinophilia–A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis", Journal of Dermatological Treatment, 2016 Mar .
Malisiewicz B, Murer C, Schmid JP, French LE, Schmid-Grendelmeier P, Navarini AA, "Eosinophilia during psoriasis treatment with TNF antagonists", Dermatology, 2013 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on denosumab (the active ingredients of Xgeva) and Xgeva (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.